Filing summary
Odyssey Therapeutics, Inc. furnished a Form 8-K on November 4, 2026, announcing financial results for the three months ended September 30, 2026. The supplied filing text does not include the contents of Exhibit 99.1, the referenced press release.
Financial results and comparisons
The filing text provided does not state revenue, profit or loss, cash flow, margins, debt, liquidity, other financial metrics, or comparative results. It also provides no clear values for these items.
Outlook, risks, and unusual items
No guidance, management commentary, risks, contingencies, or unusual items are described in the supplied text.
Key facts to verify
- Review Exhibit 99.1 for the reported quarterly results and any year-over-year or sequential comparisons.
- Check the press release for cash runway, operating expenses, clinical-program updates, guidance, and risk disclosures.
The 8-K states that the information, including the exhibit, is furnished and is not deemed filed for purposes of Section 18 of the Exchange Act, except as expressly incorporated by reference.